Bausch + Lomb is up 7.6%, or $1.47 to $20.64.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BLCO:
- BLCO Expands Dry Eye Disease Portfolio with Acquisition of Xiidra from Novartis
- Bausch Health’s Bausch + Lomb to acquire Novartis’ XIIDRA
- Bausch + Lomb to acquire Xiidra, libvatrep from Novartis for $1.75B upfront
- Novartis to divest ‘front of eye’ ophthalmology assets to Bausch + Lomb
- Bausch + Lomb to pay $1.75B to acquire dry-eye drug from Novartis, WSJ reports